drugset / Trial / NCT05703009
Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
RandomizedCrossoverQuadruple-blindTreatment
Summary
SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.
Timeline
- Start
- 2023-06-05
- Primary completion
- 2024-01-22
- Completion
- 2024-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacrosidase | Protein / enzyme biologic | 2 ml | Oral |
| Subject | Sacrosidase | Protein / enzyme biologic | 17000 iu | Oral |